Oral Session 1-8D Malignant Lymphoma: Clinical studies

[OS1-8D-4] Phase 2 study of ibrutinib in Japanese patients with relapsed/refractory MCL: final analysis

Noriko Fukuhara¹, Hirokazu Nagai², Dai Maruyama³, Toshiyuki Kitano⁴, Takayuki Ishikawa⁵, Hirohiko Shibayama⁶, Ilseung Choi⁷, Kiyohiko Hatake⁸, Toshiki Uchida⁹, Momoko Nishikori⁴, Tomohiro Kinoshita¹⁰, Yoshihiro Matsuno¹¹, Tomoaki Nishikawa¹², Kensei Tobinai³ (1.Tohoku Univ. Hosp., Sendai, Japan, 2.NHO Nagoya Med. Ctr., Nagoya, Japan, 3.National Cancer Ctr. Hosp., Tokyo, Japan, 4.Kyoto Univ. Grad. Sch. Med., Kyoto, Japan, 5.Kobe City Med. Ctr. General Hosp., Kobe, Japan, 6.Osaka Univ. Grad. Schl. Med., Osaka, Japan, 7.NHO Kyusyu Cancer Ctr., Fukuoka, Japan, 8.The Cancer Institute Hosp. JFCR, Tokyo, Japan, 9.Japanese Red Cross Nagoya Daini Hosp., Nagoya, Japan, 10.Aichi Cancer Ctr., Nagoya, Japan, 11.Hokkaido Univ. Hosp., Sapporo, Japan, 12.Janssen Pharmaceutical K.K., Tokyo, Japan)